Sales increase of 20.4% in 2H compared to 1H achievedThird party sales in CHF million
Slightly more employees due to aquisitionsNumber of employees (FTE)
Key takeaways
Well positioned
0%
EBIT margin at previous year level achieved
Thanks to the significantly improved utilization of production capacities, strict cost management and positive mix effects in the second half of the year the EBIT margin could be defended and an operating profit of CHF 227.4 million was achieved.
0
Investments in future growth, in CHF million
Expenditure on property, plant and equipment was mostly spent to realize growth projects and thus the extension of infrastructure particularly in the Medical and Automotive divisions. At CHF 104.1 million, the investment volume remained at a similar level as in the previous year (CHF 116.7 million).
Strategy tested by COVID-19 pandemicThe COVID-19 pandemic put the effectiveness of SFS’ business strategy to the test. The strategic alignment has proven to be robust and correct:
- For SFS, close customer relationships are essential. In line with the "local for local" strategy, SFS is steadily building up its global development and production platform. Thanks to short and robust supply chains a superior supply reliability was realized.
- The balanced focus on different end markets, regions and sales channels cushioned the consequences of the decline in demand.
- With its increased focus on the medical device industry SFS is attractively positioned for the future.
- Thanks to its good profitability and solid balance sheet, SFS has the means and the ability to pursue its longterm strategy and to make the associated investments even in such a crisis.
Benefited from a balanced positioningShare of sales by end market
